These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30101709)

  • 1. Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives.
    de Castro AA; da Cunha EFF; Pereira AF; Soares FV; Leal DHS; Kuca K; Ramalho TC
    Curr Alzheimer Res; 2018; 15(12):1161-1178. PubMed ID: 30101709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug repositioning for Alzheimer's disease.
    Corbett A; Pickett J; Burns A; Corcoran J; Dunnett SB; Edison P; Hagan JJ; Holmes C; Jones E; Katona C; Kearns I; Kehoe P; Mudher A; Passmore A; Shepherd N; Walsh F; Ballard C
    Nat Rev Drug Discov; 2012 Nov; 11(11):833-46. PubMed ID: 23123941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    Masters CL; Bateman R; Blennow K; Rowe CC; Sperling RA; Cummings JL
    Nat Rev Dis Primers; 2015 Oct; 1():15056. PubMed ID: 27188934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.
    Chatterjee P; Roy D; Rathi N
    J Alzheimers Dis; 2018; 61(1):53-65. PubMed ID: 29199645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug Repositioning for Alzheimer's Disease].
    Ihara M; Saito S
    Brain Nerve; 2019 Sep; 71(9):961-970. PubMed ID: 31506398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
    Kumar S; Chowdhury S; Kumar S
    BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients.
    Bayraktar A; Li X; Kim W; Zhang C; Turkez H; Shoaie S; Mardinoglu A
    J Transl Med; 2023 May; 21(1):332. PubMed ID: 37210557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular pathogenesis and development of disease-modifying drugs for Alzheimer's disease].
    Takeda M
    Seishin Shinkeigaku Zasshi; 2013; 115(1):32-40. PubMed ID: 23691792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.
    Hampel H; Schneider LS; Giacobini E; Kivipelto M; Sindi S; Dubois B; Broich K; Nisticò R; Aisen PS; Lista S
    Expert Rev Neurother; 2015 Jan; 15(1):83-105. PubMed ID: 25537424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease: Advances in Drug Development.
    Piton M; Hirtz C; Desmetz C; Milhau J; Lajoix AD; Bennys K; Lehmann S; Gabelle A
    J Alzheimers Dis; 2018; 65(1):3-13. PubMed ID: 30040716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.
    Ihara M; Saito S
    J Alzheimers Dis; 2020; 74(4):1013-1028. PubMed ID: 32144994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
    Bachurin SO; Bovina EV; Ustyugov AA
    Med Res Rev; 2017 Sep; 37(5):1186-1225. PubMed ID: 28084618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease: clinical trials and drug development.
    Mangialasche F; Solomon A; Winblad B; Mecocci P; Kivipelto M
    Lancet Neurol; 2010 Jul; 9(7):702-16. PubMed ID: 20610346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease.
    Adlard PA; James SA; Bush AI; Masters CL
    Drugs Today (Barc); 2009 Apr; 45(4):293-304. PubMed ID: 19499094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A newly designed molecule J2326 for Alzheimer's disease disaggregates amyloid fibrils and induces neurite outgrowth.
    Chang PT; Talekar RS; Kung FL; Chern TR; Huang CW; Ye QQ; Yang MY; Yu CW; Lai SY; Deore RR; Lin JH; Chen CS; Chen GS; Chern JW
    Neuropharmacology; 2015 May; 92():146-57. PubMed ID: 25596491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOTA: Deep Learning Optimal Transport Approach to Advance Drug Repositioning for Alzheimer's Disease.
    Chyr J; Gong H; Zhou X
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ameliorating effect of anti-Alzheimer's drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer's disease.
    Ahmed AS; Elgharabawy RM; Al-Najjar AH
    Exp Biol Med (Maywood); 2017 Jul; 242(13):1335-1344. PubMed ID: 28534431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.